Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Exclusion Criteria

• •1. Current, or in the past 4 weeks, treatment with other oral hypoglycemic agents and/or insulin
• •2. Diagnosis of possible or probable Alzheimer's Disease, Mild Cognitive Impairment, or any other dementia
• •3. History of neurological disorder, or evidence of neurologic or other physical illness that could produce cognitive deterioration
• •4. Severe mood episode, defined as a Hamilton Depression Rating Scale (HAMD-17) score of \>23
• •5. Actively suicidal or evaluated as being a suicide risk (operationalized as a score of ≥3 on HAMD-17 suicide item and/or by clinical assessment).
• •6. Substance use disorder within 3 months before screening or a positive baseline toxicology screen
• •7. DSM-5 diagnosis of obsessive compulsive disorder, posttraumatic stress disorder (current or within the last year), or borderline personality disorder as assessed by a study investigator
• •8. Presence of absolute or relative contraindication to semaglutide (e.g. hypersensitivity to semaglutide, hepatic impairment, renal impairment with chronic kidney disease stage 3 and above, personal or familial history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2)
• •9. History of diabetic retinopathy
• •10. History of pancreatitis or pancreatic cancer
• •11. Presence of clinically unstable general medical illness
• •12. Pregnancy or breastfeeding women